(PCR) PCC Rokita - Ratings and Ratios
Exchange: WAR • Country: Poland • Currency: PLN • Type: Common Stock • ISIN: PLPCCRK00076
PCR: Chlorine, Insulation, Cleaning, Detergents, Chemicals, Foams
PCC Rokita SA is a leading manufacturer and supplier of chemical products, operating in Poland and internationally. Established in 1993 and headquartered in Brzeg Dolny, the company specializes in the production of a wide range of chemical solutions, including chlorine and alkali products, polyurethane insulation systems, and specialty chemicals. Its product portfolio serves diverse industries such as construction, automotive, electronics, and personal care, showcasing its versatility in meeting industrial and consumer needs.
The companys product lineup includes polyols, naphthalene derivatives, and phosphorus compounds, which are essential in the production of plastics, adhesives, and firefighting agents. Additionally, PCC Rokita offers household and industrial cleaning agents, vegan personal care products, and advanced chemical solutions for water treatment and lubricants. Its commitment to innovation is reflected in its investment in R&D, focusing on sustainable and eco-friendly chemical solutions to meet growing environmental demands.
As a subsidiary of PCC SE, PCC Rokita leverages its parent companys resources and expertise to maintain a strong market presence. The companys strategic focus on quality and customer satisfaction has enabled it to build long-term partnerships across Europe and beyond. Its logistics and transport services further enhance its operational efficiency, ensuring timely delivery of products to clients worldwide.
From a financial perspective, PCC Rokitas market capitalization stands at 1431.42M PLN, with a P/E ratio of 11.82, indicating a stable valuation. The companys return on equity (RoE) of 9.39% reflects its profitability and efficient use of shareholder capital. These metrics highlight PCC Rokitas solid financial standing and its role as a key player in the commodity chemicals sector.
Looking ahead, the technical data suggests that PCC Rokitas stock may experience a period of consolidation. The SMA 20 (73.79) is slightly below the SMA 50 (74.77), while the SMA 200 (78.61) indicates long-term stability. With an ATR of 1.59, volatility is expected to remain moderate. Fundamentally, the companys focus on R&D and sustainability aligns with market trends, potentially driving growth in the coming months.
Over the next three months, PCC Rokita is likely to maintain its operational momentum, supported by steady demand across its core markets. The companys emphasis on innovation and environmental responsibility positions it well to capitalize on emerging opportunities, particularly in the personal care and industrial sectors. While external factors such as raw material costs and global market conditions may influence performance, PCC Rokitas diversified portfolio and strategic initiatives should help mitigate risks and sustain growth.
Additional Sources for PCR Stock
PCR Stock Overview
Market Cap in USD | 394m |
Sector | Basic Materials |
Industry | Chemicals |
GiC Sub-Industry | Commodity Chemicals |
IPO / Inception |
PCR Stock Ratings
Growth Rating | 45.6 |
Fundamental | 55.3 |
Dividend Rating | 85.2 |
Rel. Strength | -9.91 |
Analysts | - |
Fair Price Momentum | 90.16 PLN |
Fair Price DCF | 202.70 PLN |
PCR Dividends
Dividend Yield 12m | 15.77% |
Yield on Cost 5y | 45.09% |
Annual Growth 5y | 14.46% |
Payout Consistency | 87.6% |
PCR Growth Ratios
Growth Correlation 3m | -21.7% |
Growth Correlation 12m | -84.2% |
Growth Correlation 5y | 81.1% |
CAGR 5y | 23.44% |
CAGR/Max DD 5y | 0.56 |
Sharpe Ratio 12m | -0.20 |
Alpha | -20.09 |
Beta | 0.250 |
Volatility | 27.75% |
Current Volume | 2.9k |
Average Volume 20d | 2.9k |
As of May 09, 2025, the stock is trading at PLN 74.50 with a total of 2,926 shares traded.
Over the past week, the price has changed by -0.53%, over one month by +11.11%, over three months by +1.12% and over the past year by -14.62%.
Partly, yes. Based on ValueRay Fundamental Analyses, PCC Rokita (WAR:PCR) is currently (May 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 55.30 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PCR as of May 2025 is 90.16. This means that PCR is currently undervalued and has a potential upside of +21.02% (Margin of Safety).
PCC Rokita has no consensus analysts rating.
According to ValueRays Forecast Model, PCR PCC Rokita will be worth about 97.4 in May 2026. The stock is currently trading at 74.50. This means that the stock has a potential upside of +30.7%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 88.7 | 19.1% |
Analysts Target Price | - | - |
ValueRay Target Price | 97.4 | 30.7% |